Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,530 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,530 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $7.79, for a total value of $11,918.70. Following the completion of the sale, the chief accounting officer directly owned 47,872 shares of the company’s stock, valued at $372,922.88. The trade was a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vir Biotechnology Stock Up 4.2%

VIR stock traded up $0.32 during midday trading on Wednesday, hitting $7.82. The company’s stock had a trading volume of 1,308,854 shares, compared to its average volume of 1,784,829. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $9.97. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -2.16 and a beta of 1.69. The stock’s 50-day moving average price is $6.66 and its 200 day moving average price is $5.87.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VIR. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Barclays set a $26.00 price target on shares of Vir Biotechnology in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of Vir Biotechnology in a report on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology has an average rating of “Moderate Buy” and an average target price of $16.29.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Virtus Investment Advisers LLC raised its position in Vir Biotechnology by 82.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock worth $240,000 after buying an additional 17,966 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Vir Biotechnology in the 4th quarter worth about $414,000. Polymer Capital Management US LLC purchased a new stake in shares of Vir Biotechnology during the fourth quarter worth approximately $202,000. Quadrature Capital Ltd acquired a new stake in shares of Vir Biotechnology in the fourth quarter valued at about $300,000. Finally, Cinctive Capital Management LP grew its position in shares of Vir Biotechnology by 14.8% in the fourth quarter. Cinctive Capital Management LP now owns 27,755 shares of the company’s stock valued at $167,000 after purchasing an additional 3,572 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.